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Wyniki. Pacjent wygoH si~ bez po-
wiktan. W 15 dobie po operacji rozpoczqt
odzywianie doustne. 30 dni po operacji
zaczqt przyjmowac pokarmy state.
Wnioski. 1. Wolny przeszczep jelita
czczego jest bezpiecznq metodq rekon-
strukcji przetyku szyjnego, dajqc bardzo
dobre rezultaty funkcjonalne, wymaga
jednak doswiadczenia w technikach
zespolania naczyn 0 matej srednicy (okoto
2 mm). 2. W przypadku ubytku sk6ry szyi
nalezy uzyc dodatkowego .ptata, tak, aby
sk6r~ zszyc bez napi~cia i nie spo-
wodowac ucisku na przeszczepione jelito.
3. Dobrym ptatem do rekonstrukcji powtok
szyi u pacjenta po radioterapii jest uszy-
putowany ptat piersiowy. Uzyskujemy dzi~­
ki niemu nie tylko odpowiedniq powierz-
chni~ sk6ry z poza pola napromieniania,
ale takze dobrze ukrwionq mas~ mi~­
sniowq.
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i Onkologii w Olsztynie
INTRODUCTION: Recently adjuvant
treatment of breast cancer has become
more advisable than the CMF program
replaced by antracyclines-containing sche-
mes. There is tendency to make
therapeutical decisions by both: the doctor
and the patient.
AIM OF THE STUDY: We've tried to
analyze the criteria of qualifications of
patients to different programs of adjuvant
treatment, focusing on the role of patient in
making therapeutical decision.
MATERIALS AND METHODS: From
June 2002 to July 2003 we treated
radically 207 patients with breast
cancer.Five physicians were asked to
present the order of prognostic factors
which are taken into consideration when
the decision about the kind of adjuvant
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treatment was made. Decision about of
adjuvant chemotherapy was made
together with patient in 61 cases (short
questionnaire about the criteria of choice
of chemotherapy program was used in
these cases). In the remaining 14 patients
decision about chemotherapy was made
by a doctor.
RESULTS: For physicians the most
important factor was metastases to axillary
lymph nodes, then age of patient, grading
(G3) and also the size of breast tumor and
preferences of the patients. For patients
the most important factor was the duration
of treatment (62% of patients ), then the
amount of necessary visits during
chemotherapy (for 31 % women this factor
was the most important one), then
probability of alopecia (only for 3.2%
of patients this factor was the most
important one), probability of other
complications and the necessity to take
cytotoxic drug orally. 93% of patients
preferred treatment consisting of 4 courses
of AC.
CONCLUSIONS: In contemporary onco-
logy it is becoming more important to
make therapeutical decisions by both: the
doctor and the patient. According to the
above analysis of the factors influencing
the choice of the kind of adjuvant therapy,
some of the factors were emphases in the
process of making therapeutical decisions
by both a doctor and a patient. The most
important factors for patients were duration
of chemotherapy and the amount of ne-
cessary visits in oncological center.
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NEWER ANTIDEPRESSANTS
FOR ALLEVIATION OF TAMOXIFEN-
INDUCED HOT FLASHES
IN BREAST CANCER SURVIVORS
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BACKGROUND: Hot flashes are
symptoms of vasomotor instability reported
in least 50-60% of breast cancer survivors
taking tamoxifen. Based on information
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